Chemotherapy for metastatic melanoma
Top Cited Papers
- 2 January 2007
- Vol. 109 (3) , 455-464
- https://doi.org/10.1002/cncr.22427
Abstract
Melanoma is a neoplasm with a rising incidence. Early‐stage melanoma is curable, but advanced, metastatic melanoma almost uniformly is fatal, and patients with such advanced disease have a short median survival. Systemic therapy remains unsatisfactory, inducing complete durable responses in a small minority of patients. For the current review, the authors focused on the current role of cytotoxic chemotherapy in the treatment of metastatic melanoma and the future prospects for improvements for multiagent chemotherapy and chemotherapy combined with immunomodulatory and/or molecularly targeted agents. They discuss roles of single‐agent chemotherapy, combination chemotherapy, combinations of chemotherapy with immunomodulatory or hormone agents, biochemotherapy, and combination chemotherapy with targeted therapies. Cancer 2007;109:455–464. © 2007 American Cancer Society.Keywords
This publication has 63 references indexed in Scilit:
- Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy na??ve patients with metastatic melanomaMelanoma Research, 2006
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?European Journal Of Cancer, 2004
- Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanomaMelanoma Research, 2003
- Use of tamoxifen in the treatment of malignant melanomaCancer, 2003
- Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-?-2a in patients with metastatic melanomaCancer, 1999
- Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-upMelanoma Research, 1995
- Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials groupEuropean Journal Of Cancer, 1994
- A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanomaCancer, 1993
- Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasesCancer, 1990